Scientists track cancer Drug's journey inside patients
NCT ID NCT06308263
Summary
This early-stage study aims to understand how a new cancer drug called tuvusertib is absorbed, processed, and eliminated by the body. It will involve 12 participants with advanced solid tumors who have run out of standard treatment options. Researchers will track a tiny radioactive marker in the drug to see where it goes and how long it stays, which helps determine safe and effective dosing for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pharmaceutical Research Associates Magyarország Kutatás - Fejlesztési Kft., Klinikai Farmakológiai Vizsgálóhely
Budapest, Hungary
Conditions
Explore the condition pages connected to this study.